BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TMC435: Additional Phase IIb data

Additional data from the ongoing, double-blind, placebo-controlled, international Phase IIb PILLAR (TMC435-C205) trial in 386 treatment-naïve patients with chronic HCV genotype 1 infection showed that 79-86% of patients receiving oral TMC435 were able to stop all therapy at week 24 after meeting predefined response criteria of achieving undetectable HCV RNA levels (<25 IU/mL) at week 4 and at weeks 12, 16 and 20. Specifically, the proportion of patients with undetectable HCV RNA levels at week 4 was 77%, 68%, 76% and 79% for the 4 TMC435 regimens - 75 mg TMC435 for 12 weeks,...

Read the full 450 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >